Osnoia Wart Remover

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the removal of corns, calluses, plantar warts, flat warts, and common warts that are less than 5 mm in size.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the removal process. After soaking, the area must be dried completely.

Using an appropriate applicator, such as a toothpick or cotton swab, one drop of the medication should be applied at a time to ensure that each wart is sufficiently covered. It is important to allow the medication to fully absorb and dry after application.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, and should be maintained for a minimum duration of 2 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. The product should not be applied to warts located on the face or mucous membranes, as this may lead to adverse effects.

Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of complications. The product is also contraindicated in patients with known allergies to any of its ingredients, due to the possibility of severe allergic reactions.

Warnings and Precautions

For external use only. This product must be kept out of reach of children to prevent accidental ingestion or misuse.

General precautions should be observed when using this product. It is contraindicated for application on irritated skin or any area that is infected or reddened. Additionally, the product should not be applied to warts located on the face or mucous membranes. Individuals with diabetes or poor blood circulation should refrain from using this product, as it may exacerbate underlying conditions. Furthermore, those with known allergies to any of the ingredients in this formulation should avoid its use to prevent adverse reactions.

Patients are advised to discontinue use and consult a healthcare professional if they become pregnant or are planning to become pregnant while using the product. Persistent discomfort following application warrants immediate medical consultation to assess the situation and determine appropriate next steps.

Emergency medical assistance should be sought if any severe reactions occur, although specific instructions for such situations are not provided in the current guidelines.

Side Effects

Patients should be aware that the product is intended for external use only and must be kept out of reach of children to prevent accidental ingestion or misuse.

In the event that a patient becomes pregnant, or is planning to become pregnant while using the product, it is advised to stop use immediately and consult a healthcare professional. Additionally, if discomfort persists during the use of the product, patients should also discontinue use and seek medical advice.

These precautions are essential to ensure the safety and well-being of patients while using the product.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Osnoia Wart Remover (wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the product out of reach of children. The product is not indicated for use on warts located on the face or mucous membranes. Caution is advised to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes.

When applying the product, it is recommended that the affected area be washed first, followed by the application of the product using an applicator, such as a toothpick or cotton swab, to ensure sufficient coverage of each wart.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients or those planning to become pregnant while using this product should discontinue use immediately. It is essential for these individuals to consult their healthcare provider to discuss potential risks and appropriate management. The safety of this product during pregnancy has not been established, and caution is advised to avoid any potential adverse fetal outcomes.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. The effects on breastfed infants have not been established.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage in the provided sections of the Summary of Product Characteristics (SPL), healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdosage.

Recommended Actions In the event of an overdosage, it is essential for healthcare providers to assess the patient's clinical status and initiate appropriate supportive care. Monitoring of vital signs and symptomatic treatment should be implemented as necessary.

Potential Symptoms While specific symptoms of overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise, given the variability in individual responses to medication.

Management Procedures In the absence of specific antidotes or treatment protocols, standard overdosage management practices should be followed. This may include gastric decontamination, such as activated charcoal, if appropriate and within the timeframe of ingestion. Continuous monitoring and supportive care are critical to ensure patient safety and recovery.

Healthcare professionals are encouraged to report any cases of overdosage to the relevant authorities to contribute to the ongoing assessment of the medication's safety profile.

Nonclinical Toxicology

If pregnancy occurs or is planned during the use of the product, it is advised to discontinue use immediately due to potential teratogenic effects. No non-teratogenic effects have been specified in the available data. Additionally, there are no details provided regarding animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. Patients should be instructed not to apply the product on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. It is important to inform patients that the product should not be used on warts located on the face or mucous membranes.

Patients with diabetes or poor blood circulation should be cautioned against using this product, as it may pose additional risks. Additionally, healthcare providers should ensure that patients are aware of any allergies to the ingredients in the product, as this could lead to adverse reactions.

Patients should be advised to discontinue use if they become pregnant or are planning to become pregnant while using the product. They should also be instructed to stop use if discomfort persists, and to seek medical advice in such cases.

When using the product, patients must be reminded to avoid contact with the eyes. In the event of accidental contact, they should flush the eye with water for 15 minutes. Furthermore, patients should be informed to store the product away from direct sunlight and at room temperature, away from heat sources.

Finally, healthcare providers should encourage patients to consult a doctor if they become pregnant or are planning to become pregnant while using the product, as well as if they experience any persistent discomfort.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers. It should be stored at a temperature range of 20° to 25° C (68° to 77° F). It is essential to keep the container tightly closed to maintain the integrity of the product.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed, continuing until the wart is removed, and for a minimum duration of at least two weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Osnoia Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)